title: Analysis of chemotherapy-induced neutropenia and optimal timing for prophylactic use of G-CSF in B-cell non-Hodgkin lymphoma patients treated with R-CHOP.
abstract: BACKGROUND
  Febrile neutropenia (FN) is one of the serious complications of chemotherapy. However, the hematological nadir after chemotherapy and the timing of prophylaxis for FN remain unclear, especially for outpatients.
  
  
  METHODS
  We prospectively analyzed laboratory data from outpatients treated with a single chemotherapy regimen, rituximab (R)-CHOP, on three consultation days (days 8, 10, and 15) after chemotherapy to identify any factors that might predict the onset of the hematological nadir and the optimal timing of G-CSF prophylaxis.
  
  
  RESULTS
  A total of 100 courses of chemotherapy (total 33 patients) were analyzed. Onset of the hematological nadir was not predictable in any of the patients who had a white blood cell count (WBC) of >5,500 × 10(6)/L and/or monocyte count of >80 × 10(6)/L on day 8, and thus there was little opportunity for G-CSF prophylaxis in each treatment course. Among patients who had a WBC count of 1,500-5,500 × 10(6)/L on day 8, the monocyte count on day 8 was significantly associated with the hematological nadir. Patients who had a monocyte count of <5 × 10(6)/L on day 8, were identified as a high-risk group for neutropenia for whom G-CSF administration during the current treatment course should be considered.
  
  
  CONCLUSIONS
  Our results indicate that, in outpatients receiving R-CHOP chemotherapy, the monocyte count on day 8 is a useful marker of the hematological nadir, allowing an opportunity for G-CSF prophylaxis.
authors: Department of Bioregulatory Medicine, Ehime University Hospital, Ehime University Graduate School of Medicine, Toon, Japan.
authors: Hisaharu
authors: H
authors: Shikata
authors: Yoshihiro
authors: Y
authors: Yakushijin
authors: Jun
authors: J
authors: Yamanouchi
authors: Taichi
authors: T
authors: Azuma
authors: Masaki
authors: M
authors: Yasukawa
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001402:B-Lymphocytes / Q000187:drug effects / Q000473:pathology; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000473:pathology; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; D016179:Granulocyte Colony-Stimulating Factor; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
references: J Clin Oncol. 2007 Jul 20;25(21):3158-67
references: 17634496
references: J Clin Oncol. 2006 Jul 1;24(19):3187-205
references: 16682719
references: Leuk Res. 1985;9(1):35-50
references: 3887043
references: Blood. 1990 Feb 15;75(4):846-50
references: 2405921
references: J Clin Oncol. 2012 May 10;30(14):1715-24
references: 22493340
references: Int J Clin Oncol. 2011 Apr;16(2):118-24
references: 20924633
references: Am J Clin Oncol. 1999 Feb;22(1):103-5
references: 10025393
references: Lancet Oncol. 2006 May;7(5):379-91
references: 16648042
references: Clin Lymphoma. 2001 Jun;2(1):47-56
references: 11707870
references: Radiology. 1982 Apr;143(1):29-36
references: 7063747
references: Exp Hematol. 1986 Jan;14(1):1-8
references: 3484706
references: Blood Cells Mol Dis. 1995;21(3):192-200
references: 8673471
references: Leuk Lymphoma. 2003 Dec;44(12):2069-76
references: 14959849
references: Blood Cells. 1988;14(2-3):443-62
references: 3265879
references: N Engl J Med. 1992 Jul 2;327(1):28-35
references: 1375975
references: Blut. 1989 Mar;58(3):117-28
references: 2649187
references: Bone Marrow Transplant. 1993 Jun;11(6):489-92
references: 8334430
references: Eur J Cancer. 2011 Jan;47(1):8-32
references: 21095116
references: Blood. 1988 Jun;71(6):1529-32
references: 2453227
references: J Clin Oncol. 1996 Feb;14(2):636-43
references: 8636781
references: N Engl J Med. 2002 Jan 24;346(4):235-42
references: 11807147
references: J Biol Response Mod. 1986 Oct;5(5):481-9
references: 3095498
references: Ann Oncol. 2009 Mar;20(3):513-9
references: 19139177
references: BioDrugs. 2009;23(3):175-86
references: 19627169
references: Blood. 1991 Dec 1;78(11):2791-808
references: 1720034